• Depot
  • Watchlist
  • Glocke
  • Handeln

    • OncoSec Medical News

    0,0002 $ 0,00% +0,00 $
    In : 0,0002 € | 23.04.24 18:40:01 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3D1RU
    ISIN: US68234L4059
    US-Symbol: ONCSQ
    Typ: Aktie

    OncoSec Medical News

    18.05.23 - PR Newswire
    OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
    16.05.23 - PR Newswire
    OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    OncoSec Announces $1.33 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
    16.05.23 - PR Newswire
    OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
    OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program PR Newswire
    27.04.23 - PR Newswire
    OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
    OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ...
    11.04.23 - PR Newswire
    OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
    10.04.23 - PR Newswire
    OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    OncoSec Announces $2 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
    03.04.23 - PR Newswire
    OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
    OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma ...
    02.03.23 - PR Newswire
    Thinking about buying stock in OncoSec Medical, Diversified Healthcare, Cardio Diagnostics, Plug Power, or Macy's?
    Thinking about buying stock in OncoSec Medical, Diversified Healthcare, Cardio Diagnostics, Plug Power, or Macy's? PR Newswire
    01.03.23 - PR Newswire
    Thinking about buying stock in Reata Pharmaceuticals, OncoSec Medical, Lucira Health, B&G Foods, or Payoneer Global?
    Thinking about buying stock in Reata Pharmaceuticals, OncoSec Medical, Lucira Health, B&G Foods, or Payoneer Global? PR Newswire
    05.12.22 - PR Newswire
    OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
    OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 PR Newswire
    30.11.22 - PR Newswire
    OncoSec Announces Pricing of $3.5 Million Public Offering
    OncoSec Announces Pricing of $3.5 Million Public Offering PR Newswire
    22.11.22 - PR Newswire
    Thinking about buying stock in Abercrombie & Fitch, GoldMining, NRX Pharmaceuticals, Vipshop Holdings, or OncoSec Medical?
    Thinking about buying stock in Abercrombie & Fitch, GoldMining, NRX Pharmaceuticals, Vipshop Holdings, or OncoSec Medical? PR Newswire
    15.11.22 - PR Newswire
    OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
    OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma PR Newswire
    11.11.22 - PR Newswire
    OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
    OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma ...
    08.11.22 - PR Newswire
    OncoSec Announces Reverse Stock Split
    OncoSec Announces Reverse Stock Split PR Newswire
    04.10.22 - PR Newswire
    OncoSec Announces Pipeline Prioritization and Workforce Reduction
    OncoSec Announces Pipeline Prioritization and Workforce Reduction PR Newswire
    20.03.20 - ACCESSWIRE
    OncoSec Medical Incorporated to Present at the New York City based Investor Summit on March 25th-26th
    NEW YORK, NY / ACCESSWIRE / March 20, 2020 / OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-​stage intratumoral cancer ...
    09.06.16 - PR Newswire
    OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016
    OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 PR Newswire
    25.03.13 - PR Newswire
    OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
    OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients 45 percent of Treated Lesions Demonstrated a Durable ...
    18.03.13 - PR Newswire
    OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York
    OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »